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One of the most important problems in managing patients with cystic ﬁbrosis is
antibiotic resistance in bacteria found in the lungs. Especially gram-negative bacteria
like Pseudomonas and Burkholderia rapidly develop resistance, and the number of
antibiotics available for this group of bacteria is limited.
There is increasing understanding that the most important parameter for the effect
of most antibiotics is the so-called “time over MIC”, i.e. the time the antibiotic
concentration is above the Minimal Inhibitory Concentration of the bacteria. This is
especially important for infections with bacteria with high MICs like Pseudomonas
and Burkholderia.
To increase time over MIC we applied continuous infusion of beta-lactam antibiotics
in six patients with chronic Pseudomonas and Burkholderia infections. All patients
improved in lung function and increased body weight compared to the previous
twelve months, where antibiotics had been administered for similar time periods
(two weeks) administered as bolus injections.
We saw no adverse events. Lately, we have employed a system allowing for
continuous infusion to be performed as intravenous treatment at home.
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Background: Once daily dosing of aminoglycosides for infective exacerbations
of CF (IECF) has been widely used in recent years. While there is no evidence
of clinical beneﬁt over multiple dosing, once daily dosing is thought to be more
convenient. This convenience is limited by the slow infusion it requires and the
associated three times daily infusions of a beta-lactam. A regimen of twice daily
tobramycin and ceftazidime may be more convenient as it can be given by slow
IV bolus. This study examines the effectiveness and safety of a twice daily (BD)
regime of antibiotics by comparing it to a three-times daily (TDS) regime.
Methods: Patients requiring treatment of an IECF were randomised into the BD or
TDS group and received a combination of ceftazidime and tobramycin. Tobramycin
was given at a dose of 7mg/kg/day. Groups were compared for both treatment effect
and safety.
Results: 128 patients completed the study. FEV1 %pred improved in both groups
(BD 9.93% ±10.61, TDS 7.89% ±10.66, p = 0.30). Six patients had a rise in
creatinine 20% (but within normal values) with no difference between groups.
An overall trend to an improvement in renal function during treatment was seen.
No ototoxicity was demonstrated. Time to next exacerbation was similar for both
groups (127 vs 149 days, p = 0.89).
Discussion: Twice daily dosing of aminoglycoside and beta-lactam is a safe and
effective regimen. Treatment efﬁcacy in this study is comparable to other similar
studies. Given the possibility of cumulative dose toxicity of aminoglycosides, further
work should directly compare the effect and safety of the lower dose of tobramycin
given in this study with higher doses recommended in the literature.
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Pulmonary infection by bacteria is a major cause of mortality in the world and
discovery of antibiotics revolutionized medical care in the 20th century. However
signiﬁcant antibiotic resistance has now emerged and new methods of combating
bacteria need to be pursued. Type IIA secreted phospholipase A2 (sPLA2-IIA) hy-
drolyzes phospholipids and has been shown to have bactericidal function particularly
in killing G+ bacteria. But limited studies examine its effect on G− bacteria such
as P. aeruginosa which frequently colonize airways of patients with cystic ﬁbrosis
and are antibiotic multi-resistance. Here, we examine the role of sPLA2-IIA in
pulmonary host defense against P. aeruginosa. Our results show rhsPLA2-IIA and
bactericidal/permeability increasing protein (BPI) in vitro killed PAK, a laboratory
strain of P. aeruginosa, in a dose-dependent manner and BPI enhanced the effect
of rhsPLA2-IIA on this strain. Human BALFs efﬁciently killed PAK strain, which
was abolished by the sPLA2-IIA speciﬁc inhibitor. Compared to their littermates,
sPLA2-IIA transgenic mice were partially protected against pulmonary infection
by PAK and CHA, a clinical strain of P. aeruginosa. Using chemiluminescent
PAK strain, we showed that bacteria disseminated in a spatio-temporal manner
in WT mice and that this dissemination was reduced in transgenic mice. Finally,
intratracheal instillation of rhsPLA2-IIA improved the survival of PAK-infected
WT mice. Based on these results, we concluded that sPLA2-IIA can be considered
as an endogenous “antibiotic-like molecule” of the host and can be potentially
used directly or as antibiotics complementary therapy during multiresistant bacteria
infection.
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Current bioﬁlm models to study the efﬁcacy of anti-P. aeruginosa treatments start
from planktonic cell cultures and use glass or plastic carriers. This results in
mono-species mushroomlike bioﬁlms, whereas bioﬁlms in CF airways are rather
microcolonies, and may contain several P. aeruginosa strains and other species.
We developed an ex vivo sputum model (EVSM), by adding antibacterial substances
directly to sputum samples from CF patients. Such an EVSM may present more
realistically the situation in the CF airways: the original bioﬁlm structure is present,
the original strain(s) and phenotypes of P. aeruginosa as well as other bacterial
species are present, and the bacterial microcolonies are surrounded by alginate,
patient mucus and leukocyte DNA. This approach makes it also possible to assess
the most promising treatment for each patient individually.
The quantity of P. aeruginosa cells was determined prior to and after treatment
by means of culture and qPCR. The latter enables to quantify the noncultivable
(i.e. bioﬁlm associated) cell population as well. Prior to DNA extraction, free DNA
from the dead/damaged cells was inactivated by means of propidiummonoazide, to
amplify only DNA from living cells.
We studied the effect of combining dornase, hypertone saline, different antibiotics,
ion chelators (EDTA), bacteriophages, and/or antisense RNA by adding the active
substances to separate sputum aliquots. Thus far EDTA, the combination of
tobramycin and azithromycin, and antisense RNA directed to block the 16S rRNA
gene, proved to reduce the load of cultivable cells from 109 to below detection.
The effect of antisense RNA was found to be immediate and bacteriostatic.
